Celcuity Inc. (NASDAQ:CELC) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC) have earned an average recommendation of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $29.17.

A number of analysts have recently issued reports on CELC shares. Needham & Company LLC reiterated a “buy” rating and set a $23.00 target price on shares of Celcuity in a report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Lifesci Capital assumed coverage on shares of Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 price target for the company. Finally, Stifel Nicolaus raised their price objective on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th.

Institutional Investors Weigh In On Celcuity

Large investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new position in Celcuity in the 3rd quarter valued at about $33,000. Prospera Private Wealth LLC acquired a new position in shares of Celcuity in the third quarter worth about $35,000. Values First Advisors Inc. purchased a new position in Celcuity in the third quarter valued at about $86,000. Quest Partners LLC grew its stake in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after purchasing an additional 1,379 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Celcuity during the 3rd quarter worth approximately $119,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Price Performance

CELC stock opened at $13.19 on Monday. The company has a market cap of $489.74 million, a PE ratio of -5.05 and a beta of 0.76. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average price of $14.90 and a two-hundred day moving average price of $15.87. Celcuity has a 12-month low of $11.51 and a 12-month high of $22.19.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.